目的诊断剂量131i在分化型甲状腺癌放疗中是否存在顿抑现象。
Objective To investigate whether or not the stunning phenomenon presents with diagnostic dose of 131i in differentiated thyroid cancer radiotherapy.
结论在分化型甲状腺癌患者的131I清甲治疗中，残余甲状腺大小和131I治疗剂量是影响清甲效果的主要因素。
Conclusion The volume of thyroid residue and ablative dose are the main factors for the efficacy of 131I thyroid ablation for DTC.
相似的，在449名未曾治疗的分化型 甲状腺癌老年患者中，91%还活着，40名去世的人中只有8人死 于 甲状腺癌症。
Similarly, among 449 of his older patients with previously untreated DTC, 91% are alive, and only 8 of the 40 who died, died of thyroid cancer.
相似的，在449名未曾治疗的分化型 甲状腺癌老年患者中，91%还活着，40名去世的人中只有8人死 于 甲状腺癌症。
Similarly, among 449 of his older patients with previously untreated DTC, 91% are alive, and only 8 of the 40 who died, died of thyroid cancer.
应用推荐